MorphicLogo.jpg
Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results
November 09, 2020 07:00 ET | Morphic Therapeutic
Initiated phase 1 clinical trial for MORF-057 with results expected by mid-2021 Presented data at UEG 2020 that reinforce preclinical potency and selectivity profile of MORF-057 Received $20 million...
MorphicLogo.jpg
Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020
October 12, 2020 07:00 ET | Morphic Therapeutic
-Data validate physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α4β7 integrin--MORF-057, inhibitor of α4β7 integrin, in development to treat...
MorphicLogo.jpg
Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057
September 23, 2020 06:30 ET | Morphic Therapeutic
First orally available integrin inhibitor from MInT Platform to enter the clinicMORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel diseasePhase 1 program to assess safety...
MorphicLogo.jpg
Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit
September 21, 2020 16:45 ET | Morphic Therapeutic
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic Announces Participation in Upcoming Investor Conferences
September 03, 2020 16:30 ET | Morphic Therapeutic
WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
August 25, 2020 06:30 ET | Morphic Therapeutic
AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE...
MorphicLogo.jpg
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
August 10, 2020 07:00 ET | Morphic Therapeutic
Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...
MorphicLogo.jpg
Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020
June 29, 2020 07:30 ET | Morphic Therapeutic
Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD IND filing on track for mid-year and phase 1 clinical...
MorphicLogo.jpg
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
June 18, 2020 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic to Present at the Jefferies Virtual Healthcare Conference
May 27, 2020 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...